Skip to contentH
HCW Biologics Inc.
H
HCWBHCW Biologics Inc. Q1 2026 · 10-Q
Revenue$6.50M$6.50M+128,231.7% vs Q1 2025 Net Income$3.47M$3.47MN/M vs Q1 2025 EPS Diluted$1.39$1.39N/M vs Q1 2025 Gross Profit$6,531,930+644,710.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
HCW Biologics Inc. · CIK 1828673 · Engraved from SEC EDGAR
Operating Cash Flow-$1,575,226N/M Margins · derivedGross margin100.5%+80.5 pt vs Q1 2025
Operating margin49.8%+38861.3 pt vs Q1 2025
Net margin53.4%+43427.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end